Finally, in future reports with larger numbers of patients, inclusion criteria should be limited to only one pathologic tumor type (GBM or AO or AA) with additional consideration of the genetic and micromolecular features of each patient's tumor (e.g., IDH1, MGMT promoter methylation, etc.), especially for OS analysis. Here, MGMT is linked to glioblastoma.